Nice find. Here's another important point lost on those who think Leo should sell or accept a buy out for a few dollars a share:
... extensive preclinical research on Kevetrin shows the re-activation of p53 across a wide spectrum of cancer lines including colon, lung, breast and pancreatic cancers. The market potential for Kevetrin in treating drug-resistant cancers is worth $5 billion a year. Other cancers could easily represent an additional $5 billion annually,... emohasis added